Vitamin B3 shows promise for glaucoma patients
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A world-first clinical trial led by the Center for Eye Research Australia has shown that vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma. Researchers show "significant improvement" in the visual function of glaucoma patients who received a daily high dose of 3 grams of nicotinamide for 12 weeks in addition to their regular treatment to reduce eye pressure.

Glaucoma is the world's leading cause of irreversible blindness, affecting more than 60 million people worldwide. The disease, which leads to vision loss when cells in the optic nerve and retina are lost, is usually treated with eye drops or surgery to reduce eye pressure. However, there are currently no treatments to protect cells from further damage or to improve cell function. CERA's trial followed 57 patients, all of whom received both placebo and vitamin B3 over the course of the study. The visual function of patients was tested using electroretinography, a diagnostic test that measures electrical activity in the cells of the retina, and visual field testing to determine any changes that occurred. The trial found that in some people, high-dose nicotinamide significantly improved how nerve cells were functioning in the eye. A larger trial is now being planned to assess whether these improvements can help reduce disease progression over a longer period. Earlier pre-clinical research in the US showed that vitamin B3 could prevent optic nerve degeneration—but this is the first time similar results have been witnessed in a human trial.

Source: https://medicalxpress.com/news/2020-07-vitamin-b3-glaucoma-patients-clinical.html
Dr. A●●●●●l S●●●●a and 1 others like this1 share
Like
Comment
Share